Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MRNA

This Is What Whales Are Betting On Moderna

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

What Are Whales Doing With Moderna

A whale with a lot of money to spend has taken a noticeably bullish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 19 strange trades.

Benzinga

What Are Whales Doing With Moderna

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 13 strange trades.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

This Is What Whales Are Betting On Moderna

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Moderna's Bivalent COVID-19 Booster Shows Antibody Response Against Omicron Subvariants

Moderna Inc (NASDAQ:MRNA) has released new clinical data on its bivalent (omicron) COVID booster candidate, mRNA-1273.214. One month after administration in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited potent neutralizing antibody responses against the omicron subvariants BA.4 and BA.5. The company is working on completing regulatory submissions…

Benzinga

Moderna To establish New Vaccine Facility In Britain

Moderna Inc (NASDAQ:MRNA) announced an agreement with the United Kingdom government to establish an mRNA Innovation and Technology Center in the U.K. Additionally, Moderna plans to expand its presence in the U.K. through investments in R&D activities. Moderna is collaborating with the National Institute for Health Research on a Phase 3 study…

Benzinga

Looking At Moderna's Recent Whale Trades

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Moderna Plans COVID-19 Vaccine Trial For Infants: WSJ

Moderna Inc (NASDAQ: MRNA) is reportedly planning to evaluate its COVID-19 vaccine in infants aged three months to 6 months.

Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth $3,600 Today

Moderna (NASDAQ:MRNA) has outperformed the market over the past 10 years by 32.14% on an annualized basis producing an average annual return of 42.94%. Currently, Moderna has a market capitalization of $49.53 billion.

Benzinga

FDA Committee Backs Moderna's COVID-19 Shot For Kids, Adolescents: Report

Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine received unanimous backing from the FDA's committee of independent immunization experts for children ages 6 through 17.

Benzinga

Moderna's COVID-19 Shot Likely Related To Higher Heart Inflammation Risk Than Pfizer's: Reuters

Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine may relate to a higher risk of heart inflammation in some age groups than Pfizer Inc (NYSE:PFE) - BioNTech SE's (NASDAQ:BNTX) shot, Reuters reported citing the Centers for Disease Control and Prevention. Citing recent data, CDC said that the findings on myocarditis and pericarditis, types of heart inflammation linked to both the…

Benzinga

Looking At Moderna's Recent Whale Trades

Benzinga

Why Moderna Stock Is Moving Lower Today

Moderna Inc (NASDAQ: MRNA) shares are trading lower Thursday as vaccine stocks fall in sympathy with Novavax Inc (NASDAQ: NVAX) following reports the FDA's decision on the company's COVID-19 vacci

Benzinga

US Schedules Covid-19 Vaccines For Children Below Five Years

The U.S. government is preparing to launch vaccines for children below five in conjunction with educational and outreach efforts, pending approval by federal regulators, the Wall Street Journal reports. The government looks to provide ten million initial doses as the virus spreads nationwide, leaving the parents anxious. The vaccinations could begin…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Moderna's Updated COVID-19 Shot Boosts Omicron Protection

Moderna Inc (NASDAQ: MRNA) has

Benzinga

Expert Ratings for Moderna

Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:

Benzinga

Moderna Commences Late-stage Study of Flu Vaccine Candidate

Moderna, Inc. (NASDAQ: MRNA) today announced Initiation of Patient dosing in the phase 3 clinical study of its seasonal influenza vaccine candidate mRNA-1010 for patients with influenza.

Benzinga

Check Out What Whales Are Doing With MRNA

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

This Famed Company Is Working On A Potential Monkeypox Vaccine

As cases of monkeypox continue to rise, Moderna Inc (NASDAQ: MRNA) is probably working on its platform towards finding a vaccine shot against the disease.

Benzinga

Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years

Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 102.55% on an annualized basis producing an average annual return of 112.95%. Currently, Moderna has a market capitalization of $54.60 billion.

Benzinga

Looking At Moderna's Recent Whale Trades

Benzinga

Moderna's Chairman Defends Executive Hiring Process After Firing New CFO In Just One Day

Moderna Inc’s (NASDAQ: MRNA) chairman comes forward with a determined defense of the board’s executive hiring process after being forced to fire its new chief financial officer just a day after taking charge.

Benzinga

Here's How Much $1000 Invested In Moderna 5 Years Ago Would Be Worth Today

Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 105.44% on an annualized basis producing an average annual return of 116.6%. Currently, Moderna has a market capitalization of $56.68 billion.

Benzinga

Moderna Concludes FDA Submission For Its COVID-19 Shot In Adolescents, Kids

Reuters reported that Moderna Inc (NASDAQ:MRNA) had made required submissions to the FDA for emergency use authorization of its COVID-19 vaccine in adolescents and children. An advisory panel of experts to the U.S. drug regulator will meet in June to review the request. Related: FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For…

Benzinga

Why Did Moderna CFO Exit Just A Day After Taking Charge

Moderna Inc (NASDAQ:MRNA) announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the company, effective immediately. The announcement follows the public disclosure by Gomez's former employer, Dentsply Sirona Inc (NASDAQ:XRAY), of an ongoing internal investigation into some issues, including financial reporting. The audit investigates Dentsply Sirona's "use of incentives to sell products to…

1 … 3 4 5 6

People

Stephane Bancel

28 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.